Myocardial fibrosis is a common pathological feature in many cardiovascular diseases, yet effective targeted therapies remain elusive. Given the emerging potential of chimeric antigen receptor T (CAR‐T) cell therapy in nononcological diseases and fibroblast activation protein (FAP) as a promising target, we engineered a second‐generation FAP‐targeted CAR construct incorporating the 4‐1BB costimulatory domain to enhance therapeutic safety. Using two delivery approaches—lentiviral vectors and lipid nanoparticles (LNPs)—we generated FAP‐CAR–engineered Jurkat cells as a preliminary screening model and evaluated their CAR expression, target recognition, and in vitro cytotoxic activity. These engineered cells selectively recognized and induced apoptosis in FAP‐expressing cardiac myofibroblasts without triggering excessive IL‐6 secretion, supporting their potential for fibrosis‐selective cytotoxicity. Our findings provide key preliminary in vitro evidence supporting the design and target‐specific functionality of FAP‐targeted CAR constructs incorporating the 4‐1BB domain, warranting further investigation in primary T cell models for cardiac fibrosis therapy.